Related Experiment Videos
[Experience with clarithromycin in pediatric patients]
K Iguchi1, H Kawaguchi, H Kamiya
1Department of Pediatrics, School of Medicine, Mie University.
Insights
Clarithromycin (TE-031) demonstrated high efficacy in treating pediatric infections, with an 88.5% success rate. A single case of transient transaminase elevation was noted, resolving upon antibiotic discontinuation.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antibiotic Therapy
Context:
- Novel macrolide antibiotic development
- Clinical evaluation of new antimicrobial agents
- Management of infections in pediatric populations
Purpose:
- To assess the clinical efficacy and safety of Clarithromycin (TE-031) in children
- Determine the effectiveness of TE-031 against pediatric infections
- Evaluate adverse events associated with TE-031 treatment
Summary:
- Clarithromycin (TE-031) achieved an 88.5% clinical efficacy rate in 26 pediatric patients with infections.
- A single instance of transaminase elevation was observed, which resolved after discontinuing the antibiotic.
- The study indicates TE-031 is a highly effective antibiotic for pediatric infectious diseases.
Impact:
- Provides evidence for Clarithromycin's utility in pediatric infectious disease treatment.
- Highlights a favorable safety profile with manageable side effects.
- Supports the use of novel macrolides in pediatric clinical practice.
Abstract:
Clarithromycin (TE-031, A-56268), a newly synthesized macrolide antibiotic, was administered to children and its efficacy was examined. The clinical efficacy rate of TE-031 was 88.5% in 26 patients with pediatric infections. This rate was regarded as quite high. A side effect, transaminase elevation, was observed in 1 out of the 26 patients but it was subsided after a cessation of the antibiotic treatment. TE-031 was considered to be effective antibiotic for the infectious disease in the pediatric fields because of highly efficacy rate.